Comparative evaluation of clinical anxiolytic efficacy of Sitadi Agada and Imipramine (TCAs) in the management of Generalized Anxiety Disorders (GAD)- A reverse Pharmacology approach.

I0 sites0 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sponsor

•a)Patient willing to sign the consent form.
•b)Patients of either sex with age between 18 to 60 years.
•c)Patient fulfilling the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM â?? IV).
•e)Patient who score at least 14 on the Hamilton Anxiety Rating Scale (HARSâ?? A) at baseline visit.

•a)Patient who suffers Anxiety due to direct physiological effect of a substance (e.g. alcohol etc) or a general medical condition (e.g. Hyperthyroidism).
•b)Occurrence of anxiety exclusively during mood disorder, a psychotic disorder or a pervasive development disorder.
•c)Patients having history of chronic diseases like Diabetes Mellitus, Ischemic Disease, Dyslipidemia, Hypertension, Malignancies, Chronic Renal Failure,
•Any Endochrinological disorders etc. will be excluded.
•d)Patients who have completed participation in any other clinical trial during the past six months.
•e)Pregnant or lactating women.
•f)Any other condition which the investigator thinks may jeopardize the study.
•g)Patients receiving Anxiolytic Drugs will be excluded.

Not specified